110 related articles for article (PubMed ID: 17124024)
1. Accounting for ACUITY.
Bittl JA
N Engl J Med; 2006 Nov; 355(21):2249-50. PubMed ID: 17124024
[No Abstract] [Full Text] [Related]
2. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
4. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
[TBL] [Abstract][Full Text] [Related]
5. ACUITY-PCI: one drug does not fit all.
Waksman R
Lancet; 2007 Mar; 369(9565):881-2. PubMed ID: 17368130
[No Abstract] [Full Text] [Related]
6. The future of an illusion.
Bittl JA
J Am Coll Cardiol; 2006 Jun; 47(12):2380-3. PubMed ID: 16781362
[No Abstract] [Full Text] [Related]
7. Bivalirudin for mechanical rotational atherectomy: the quest for better outcomes.
Shenoy C; Harjai KJ
J Interv Cardiol; 2010 Jun; 23(3):230-2. PubMed ID: 20636843
[No Abstract] [Full Text] [Related]
8. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
10. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation during percutaneous coronary intervention in diabetics--is simpler always better?
Meier P; Gurm HS
J Invasive Cardiol; 2010 Mar; 22(3):101-2. PubMed ID: 20197574
[No Abstract] [Full Text] [Related]
12. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
[TBL] [Abstract][Full Text] [Related]
13. Should bivalirudin replace heparin during percutaneous coronary interventions?
Antman EM
JAMA; 2003 Feb; 289(7):903-5. PubMed ID: 12588276
[No Abstract] [Full Text] [Related]
14. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy to support primary PCI.
Morrow DA
N Engl J Med; 2008 May; 358(21):2280-2. PubMed ID: 18499573
[No Abstract] [Full Text] [Related]
16. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
18. Letter by De Servi and Navarese regarding article, "Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial".
De Servi S; Navarese E
Circulation; 2010 Sep; 122(12):e461; author reply e462-3. PubMed ID: 20855666
[No Abstract] [Full Text] [Related]
19. Direct thrombin inhibitors (part 2 of 2).
Arora UK; Dhir M
J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
[No Abstract] [Full Text] [Related]
20. HORIZONS-AMI.
Webster MW
Lancet; 2010 Jan; 375(9712):375. PubMed ID: 20113821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
